Drug Trial Radar · NCT00436033
A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 11, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,429
Actual
Start
Feb 2006
Primary completion
Sep 2007
Study completion Sep 2007
Sponsor
- Lead sponsor
- Pierre Fabre MedicamentIndustry
- Sponsor type
- Industry
- First posted
- Feb 16, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome.
Conditions
- Fibromyalgia Syndrome
Interventions
milnacipranDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the efficacy of treatment with milnacipran as compared to placebo in the treatment of the fibromyalgia syndrome in outpatients after a 12-week period of fixed dose exposure through a primary composite criterionTime frame: 12 weeks
Locations
13 sites in 13 countries. Site status is shown where the registry gives one.
Rheumatology Ambulance
Pardubice, Czechia
FREDERIKSBERG HOSPITAL - Clinic of Rheumatology
Frederiksberg, Denmark
Kuopion Oma Laakari Oy
Kuopio, Finland
Hopital Hotel Dieu
Paris, France
KKSK KLINIKUM DER UNIVERSITAET ZU KOELN - Anaesthesiology and Intensive Care
Cologne, Germany
Ospedale Luigi Sacco
Milan, Italy
Center For Clinical Studies
Lillehamer, Norway
"Nasz Lekarz"
Torun, Poland
Hospital Egas Moniz
Lisbon, Portugal
Dr I CANTACUZINO CLINICAL HOSPITAL
Bucharest, Romania
Hospital de La Esperanza
Barcelona, Spain
Gottfriesclinic Ab
Mölndal, Sweden
KINGS COLLEGE HOSPITAL - Clinic Trial Unit Academic Department of Rheumatology
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.